Drug Database
ME

mesalazine (Mesasal / Claversal)

✓ Approved

GSK · PTGS1 · 小分子

什么是 mesalazine?

mesalazine 是一种小分子,由GSK研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Mesasal, Claversal
公司GSK
药物类别小分子
分子靶点PTGS1, PTGS2
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

mesalazine 作用于 2 个分子靶点:

PTGS1prostaglandin-endoperoxide synthase 1 (COX3, PCOX1)
PTGS2prostaglandin-endoperoxide synthase 2 (GRIPGHS, hCox-2)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

mesalazine 针对 3 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Gastrointestinal disordersInflammatory bowel disease✓ Approved
Gastrointestinal disordersColitis ulcerative✓ Approved
Gastrointestinal disordersCrohn's disease✓ Approved

相关研究文献

PubMedInflammatory bowel diseases2026-11-04

Multi-matrix metabolome and microbiome profiling in diarrhea-predominant irritable bowel syndrome and ulcerative colitis in remission with IBS-like symptoms.

Chen Guorong G, Du Shiyu S, Li Hui H, Wang Huifen H et al.

Irritable bowel syndrome (IBS)-like symptoms frequently persist in patients with ulcerative colitis (UC) in remission. Whether UC in remission with IBS-like symptoms (UCR-IBS) represents functional overlap with diarrhea-predominant IBS (IBS-D) or a distinct metabolic phenotype remains unclear. In this exploratory cross-sectional study, 39 patients with IBS-D, 21 with UCR-IBS, and 35 healthy controls were enrolled. Serum, urine, fecal, and colonic mucosal samples were collected. Untargeted metabolomics, targeted tryptophan profiling, fecal 16S ribosomal RNA gene sequencing, predicted microbial functional profiling, and microbe-metabolite association analyses were performed. Tryptophan-related metabolism was altered in both patient groups, but the patterns differed across biological matrices. Compared with IBS-D, UCR-IBS showed higher serum N-formylkynurenine (NFK) concentrations, and fecal findings suggested reduced concentrations of microbiota-associated indole metabolites. Microbiome differences were modest, but predicted nicotinate/nicotinamide metabolism was enriched in UCR-IBS. Exploratory network analysis identified associations between tryptophan-related metabolites and selected bacterial genera in each group. Multi-matrix profiling shows tryptophan-related metabolic differences between mesalazine-treated UCR-IBS and IBS-D, highlighting higher serum NFK concentrations in UCR-IBS. These findings provide a basis for investigating host-microbiota metabolic relationships across systemic and intestinal compartments during UC remission.This trial was registered in the Chinese Clinical Trial Registry (ChiCTR; https://www.chictr.org.cn/) under registration number ChiCTR2200060224.

PMID 42981088
阅读全文 →
PubMedPharmaceuticals (Basel, Switzerland)2026-10-27

Changing Prescription Patterns in Pharmacologically Treated Patients with Newly Diagnosed Inflammatory Bowel Disease in German Gastroenterology Practices: A Real-World Study, 2015-2024.

Fernandez Milano Annika A, Krieg Sarah S, Kostev Karel K

Background/Objectives: The therapeutic landscape of inflammatory bowel disease (IBD) has evolved, particularly with the expanding availability of biologic and targeted therapies. This study characterized real-world prescribing patterns among patients with newly diagnosed Crohn's disease (CD) and ulcerative colitis (UC) in Germany. Methods: This retrospective study used the German IQVIA Disease Analyzer database. Patients aged 15-80 years diagnosed with CD or UC between 2015 and 2024, with ≥12 months of follow-up and at least one predefined treatment prescription within 12 months after diagnosis, were included. Prescription patterns were compared by IBD subtype, diagnosis period (2015-2019 vs. 2020-2024), age, and sex. Associations were assessed using multivariable logistic regression. Results: Overall, 10,009 patients were included (CD, n = 3810; UC, n = 6199). Mesalazine remained predominant in UC (89.7% in 2015-2019 vs. 87.9% in 2020-2024), whereas biologics were prescribed more frequently in CD and were more common in the later diagnosis period (CD: 32.2% vs. 54.0%; UC: 14.6% vs. 21.5%). UC was associated with higher odds of mesalazine prescription (OR 15.17) and lower odds of biologic prescription (OR 0.28) compared with CD. The later diagnosis period was associated with higher odds of biologic prescription (OR 2.00) and lower odds of mesalazine (OR 0.67) and thiopurine prescription (OR 0.59). Prescription patterns also differed by age, whereas sex-related differences were limited. Conclusions: Among pharmacologically treated patients with newly diagnosed IBD, prescription patterns differed substantially between diagnosis periods, with more frequent biologic and less frequent thiopurine and mesalazine prescriptions in the later period, particularly in CD. Patterns also differed by IBD subtype and age.

PMID 42943287
阅读全文 →
PubMedPharmaceutics2026-10-27

A Mesalazine-Aloperine Co-Amorphous System for Simultaneous Dissolution Enhancement, Permeability Improvement, and Synergistic Anti-Ulcerative Colitis Activity: A Combined Pharmaceutics and Network Pharmacology Study.

Su Huan H, Guo Ningzi N, Yuan Song S, Huang Junyi J et al.

Background/Objectives: Mesalazine (MSZ), the first-line therapy for ulcerative colitis (UC), is a BCS Class IV drug limited by poor aqueous solubility and low intestinal permeability, which together restrict colonic drug delivery and therapeutic efficacy. This study aimed to develop a co-amorphous (CAM) system of MSZ and aloperine (ALO) to enhance MSZ dissolution and permeation while achieving anti-UC synergy. Methods: The MSZ-ALO CAM system was prepared via solvent evaporation and characterized by PXRD, DSC, FTIR, and 1H NMR. Equilibrium solubility, intrinsic dissolution rate (IDR), and in vitro permeability were assessed under biorelevant pH conditions. Physical stability was evaluated under long-term and accelerated conditions. Network pharmacology predicted potential therapeutic targets and synergistic mechanisms. Results: Solid-state characterization confirmed a homogeneous single-phase CAM system stabilized mainly by a carboxylate-ammonium ionic bond and hydrogen bonding. At pH 4.5, where MSZ solubility was lowest, equilibrium solubility and IDR increased up to 71.9-fold and 35.8-fold, respectively. In vitro permeability at pH 6.5 increased 2-fold. The system remained physically stable for eight months under dry conditions and withstood accelerated stresses without recrystallization. Network pharmacology identified 51 shared targets among MSZ, ALO, and UC, enriched in MAPK, HIF-1, and AMPK pathways; core hubs included HSP90AA1, SRC, CASP3, GSK3B, and ALB. Conclusions: This study presented the first MSZ-ALO CAM system that simultaneously addresses the dual solubility and permeability barriers of MSZ and provided a multi-target pharmacological basis for synergistic UC therapy, offering a promising pharmaceutical strategy for colon-targeted delivery.

PMID 42942819
阅读全文 →
PubMedJournal of clinical medicine2026-10-27

Cutaneous Events After Recombinant Zoster Vaccination and Shoulder Injury Related to Zoster Vaccine Administration: A Narrative Review.

Ciccullo Carlo C, Ciccullo Arturo A, Farah Sonia S, Bevilacqua Claudia C et al.

Background: Herpes zoster results from the reactivation of varicella-zoster virus (VZV), with incidence increasing with age and immunosuppression. The recombinant zoster vaccine (RZV, Shingrix®, GlaxoSmithKline Biologicals SA, Rixensart, Belgium) has demonstrated high efficacy in preventing herpes zoster and its complications. Methods: We conducted a narrative review of English-language publications addressing cutaneous events, musculoskeletal events, and shoulder injury related to vaccine administration following recombinant zoster vaccination. Original studies, pharmacovigilance analyses, case reports, case series, and relevant reviews published up to 31 January 2026, were considered. Results: Available evidence on cutaneous and musculoskeletal events following recombinant zoster vaccination was limited and heterogeneous. Reported cutaneous events included inflammatory and hypersensitivity-type reactions, vesicular or bullous eruptions, and episodes of VZV reactivation occurring in temporal proximity to vaccination. In virologically confirmed cases, the detected VZV strains were wild-type, consistent with reactivation of latent wild-type virus. Musculoskeletal symptoms, including arthralgia and myalgia, were more commonly reported but were generally mild and self-limiting. Evidence concerning SIRVA was limited and restricted to a single case report following intramuscular zoster vaccine administration. Conclusions: Current evidence supports a favorable safety profile for Shingrix®. Cutaneous events are uncommon and heterogeneous, while evidence concerning SIRVA is limited to a single case report following zoster vaccination, precluding estimates of incidence or a product-specific association. Proper injection technique and continued pharmacovigilance remain essential.

PMID 42941477
阅读全文 →
PubMedPharmaceutics2026-10-27

Ethyl Cellulose-Coated Cylindrical Granules for Multi-Unit Sustained-Release Tablets: Trade-Off Between Coating Integrity, Compressibility, Tabletability, and Drug Release.

Li Zhaohua Z, Fan Ying Y, Yang Jingxi J, Zhang Guangshuai G et al.

Background: Cylindrical granules, rather than spherical pellets, are used in certain multi-unit sustained-release tablets (MUSTs), such as mesalazine (MSZ) sustained-release tablets (Pentasa®). Our previous studies established that porosity and aspect ratio govern the tableting behavior of uncoated cylindrical MSZ granules. However, it is unknown how the compressibility, tabletability and release behavior of the coated cylindrical granules will change. Methods: In this study, ethyl cellulose (EC) was used as a model sustained-release coating polymer to systematically investigate the effects of EC coating film on the compressibility, tabletability, and drug-release performance of MSZ cylindrical granules. Results: It was found that increasing EC molecular weight and coating weight gain compromised the compressibility of the coated cylindrical granules, as reflected by increased yield stress values. Structural analysis demonstrated that thicker coatings and higher-molecular-weight EC films were less susceptible to compression-induced damage, preserving coating integrity after tableting. However, this enhanced coating robustness was accompanied by reduced tabletability, as reflected by lower tablet tensile strength at a given compaction pressure. In addition, increasing EC molecular weight and coating weight gain progressively reduced MSZ release from both coated granules and corresponding tablets. Conclusions: These findings demonstrate a trade-off among coating integrity, compressibility, tabletability, and drug-release control in MUST development. The results provide a mechanistic basis and practical guidance for optimizing coated cylindrical granules and balancing coating protection with tablet manufacturability and sustained-release performance.

PMID 42942753
阅读全文 →
PubMedCrohn's & colitis 3602026-10-27

International practice patterns in the management of pouchitis: results from a global survey.

Fanizzi Fabrizio F, D'Amico Ferdinando F, Galbiati Maria M, Jairath Vipul V et al.

Pouchitis is the most frequent long-term complication after ileal pouch-anal anastomosis (IPAA) for ulcerative colitis. This study aimed to describe current international practices, definitions, and treatment strategies among experienced clinicians. An international web-based survey was conducted in 2025, following CROSS guidelines, exploring diagnostic, monitoring, and therapeutic practices. Responses were anonymized and analyzed descriptively. A total of 412 physicians from 49 countries completed the survey, mostly gastroenterologists involved in IBD care (362/412, 87.8%). Most clinicians (156/412, 37.9%) estimated a pouchitis prevalence of 26%-50% among patients with IPAA, typically occurring within the first postoperative year. Follow-up was scheduled every 3-6 months by 164/412 (39.8%) physicians, with nearly half (47.6%) reporting the use of the pouch disease activity index (PDAI). Fecal calprotectin was the preferred non-invasive monitoring tool (326/412, 79.1%), whereas intestinal ultrasound was selected by 130/412 respondents (31.69%). Endoscopy was the primary diagnostic and follow-up modality (398/412, 96.6%), with biopsies routinely taken (364/412, 88%), although 46.7% of respondents reported not using a standardized histological scoring system. Prophylactic therapy was prescribed by 222/412 (53.9%), mainly probiotics (27.7%) and rectal mesalazine (18.2%). In acute pouchitis, ciprofloxacin plus metronidazole was the preferred first-line regimen (218/412, 52.9%). For chronic antibiotic-dependent or refractory pouchitis, advanced therapies were the predominant first-line option (254/412, 61.7%), with vedolizumab (198/412, 48.1%), and infliximab (170/412, 41.3%) most frequently selected. Ustekinumab, selective IL-23 inhibitors, JAK inhibitors and S1P receptor modulators were increasingly used in refractory cases. Treatment targets were primarily clinical (156/412, 37.9%) and endoscopic (124/412, 30.1%) remission, and most respondents (246/396, 62.1%) reported performing endoscopic assessment within 3-6 months after advanced treatment initiation. This international survey demonstrates substantial heterogeneity in pouchitis diagnosis, monitoring, and treatment, highlighting important gaps in standardized disease assessment and treatment strategies. The findings support the need for consensus-based approaches and prospective, pouch-specific studies to improve the standardization of pouchitis care.

PMID 42936095
阅读全文 →

注册免费账户还可查看另外 3996 篇文献

免费注册查看全部文献 →

了解更多mesalazine